Skip to content
zynerba logo
CONNECT-FX is recruiting Fragile X patients: Click here for more information
  • Investors
    • IR Information
    • Stock Information
    • Press Releases
    • Events & Webcasts
    • Presentations
    • Financial Information
    • Analyst Coverage
    • Corporate Governance
    • Investor FAQs
    • IRS Form 8937
    • Investor Contacts
  • News
    • Press Releases
    • Events
  • Publications
    • Manuscripts and Presentations
  • Careers
  • LinkedIn
  • Twitter
  • Our Focus
    • Why Rare?
    • Why Neuropsychiatric Disorders?
    • Why Cannabinoids?
    • Why pharmaceutical manufacturing?
  • Our Pipeline
    • ZYN002 CBD Gel
    • CONNECT-FX Trial
    • Early Access to Medicine
  • Clinical Trials
  • Our Team
    • Management
    • Board of Directors
    • Scientific Advisory Board
  • Patient Resources
    • FXS
    • ASD
    • 22q
    • DEE
    • Epilepsy

Zynerba Press Releases

31 Jul 18 Zynerba Pharmaceuticals to Host Conference Call to Provide Second Quarter 2018 Business Update

20 Jul 18 Zynerba Pharmaceuticals Announces Pricing of Public Offering of Common Stock

19 Jul 18 Zynerba Pharmaceuticals Announces Proposed Public Offering of Common Stock

12 Jul 18 Zynerba Pharmaceuticals Announces New FAB-C Phase 2 Open-Label Data in Patients with Fragile X Syndrome

9 Jul 18 Zynerba Pharmaceuticals Initiates CONNECT-FX, a Pivotal Clinical Trial of ZYN002 in Fragile X Syndrome

5 Jul 18 Zynerba Pharmaceuticals Announces Top Line Results from ZYN001 THC-Prodrug Patch Phase 1 Study

31 May 18 Zynerba Pharmaceuticals to Present at the Jefferies 2018 Global Healthcare Conference

8 May 18 Zynerba Pharmaceuticals Reports First Quarter 2018 Financial Results and Operational Highlights

25 Apr 18 Zynerba Pharmaceuticals Announces Twelve Month ZYN002 Data from STAR 2 Study in Patients with Focal Seizures at the 2018 Annual Meeting of the American Academy of Neurology (AAN)

23 Apr 18 Zynerba Pharmaceuticals Announces Oral Presentation of ZYN002 Data at the 16th NFXF International Fragile X Conference in July 2018

Page 2 of 9 | 1 2 3 4 5 6 7 8 9

    This site uses cookies to give you a better browsing experience. By continuing to use this website, you accept our use of these cookies. For more information, see our Privacy Notice.

    • Privacy Policy
    • Terms of Use
    • Contact Us

    © 2019 Zynerba Pharmaceuticals, Inc. All rights reserved.

    zynerba inverted logo

    80 W. Lancaster Avenue, Suite 300
    Devon, PA 19333
    484.581.7505